Researchers at the University of California, San Diego School of Medicine concluded that aspirin, in addition to preventing pain and inflammation, actually helps hasten the end of inflammation in a study published this week in the online early edition of PNAS.
Nearly half of women age 45 years or older who experience symptoms of overactive bladder report their current treatment does not address their OAB symptoms, according to a recent survey conducted by The Harris Poll on behalf of Allergan.
DSN senior editor Michael Johnsen examines in-depth sales activity in pain, cough-cold, overactive bladder, allergy and more, highlighting new products that are transforming OTC in this multi-page report.
The National Advertising Division on Wednesday determined that Chattem can support certain advertising claims for “Nasacort Allergy 24HR,” an over-the-counter allergy relief medication. The claims were challenged by Merck Consumer Care.
A sizeable proportion of men (39%) report removing body hair below the neck, otherwise known as manscaping, according to the Multi-sponsor Survey’s 2014 Study of Men’s Grooming Appliances and Tools released today.
America’s biopharmaceutical research companies are developing 435 innovative new medicines to target 15 leading chronic conditions affecting the Medicare population, according to a new report released by the Pharmaceutical Research and Manufacturers of America last week.
The U.S. Global Research Program in May issued an 800-page National Climate Assessment report that does not bode well for the more than 50 million Americans with allergies and asthma — their already terrible symptoms are about to get worse.
With the ragweed season getting longer and longer, according to government reports, allergy has become a significant driver behind trips to the eye care aisle, and represents a much broader potential patient base. In response to rising temperatures, ragweed pollen season length increased between 1995 and 2011 by as much as 11 days (to 27 days) in parts of the United States and Canada.
Mylan on Wednesday announced the launch of risedronate sodium tablets USP, 150 mg. The drug is the generic version of Actonel tablets from Warner Chilcott and is used for the treatment of osteoporosis in post-menopausal women, according to the company.